Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaAsparaginase pharmacokinetics and implications of therapeutic drug monitoringHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaCrystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding siteHLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginaseEffect of premedications in a murine model of asparaginase hypersensitivityThe best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia.A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.Studies on Deimmunization of Antileukaemic L-Asparaginase to have Reduced Clinical Immunogenicity--An in silico Approach.The anti-asparagines antibodies correlate with L-asparagines activity and may affect clinical outcome of childhood acute lymphoblastic leukemia.Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.Clinical significance of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
P2860
Q26738640-6DD74276-3D71-4E73-9208-E5498F8336E6Q27026476-A37E394C-E104-4560-B40D-0AC305B4A1D4Q27026952-3F1E7D44-01F4-4C0F-B635-131B55E25F85Q27694569-4F683201-1965-4EE2-AC41-4069540762C6Q30371340-C2849E01-E345-426A-9672-BF69FF3D499AQ34400424-20CDCFB6-201B-45BF-B09E-2BEAC7AFF371Q35156439-5D6E2686-5E69-451E-82B2-90238A57D411Q35732108-AB91CA54-3C97-42CC-BDB7-6151393AB175Q36284750-A053F9D8-9169-40F7-B2A6-65DDA97BB42FQ36762608-5825D0ED-6C6F-40F7-9803-DF20B64A51EEQ36918761-632C2CC7-74F7-4488-B3B2-2753AF54C2CFQ37670065-0A714F04-EF3F-4690-A111-D3A7A61FD20CQ38040418-530C49D7-E6CA-4E78-AFF5-314D803B4C36Q38696311-753AC9E3-93CE-4380-85DA-5E02F8F080A3Q38880102-F2B30A3A-C976-4267-BB1B-39B683DB2067Q38933372-2DDCB5A6-055F-47FE-8AD8-2D2871A75F3AQ39194553-FD523400-70DE-41CB-8592-321A8E34BFE2Q41150769-931B2FC8-FC2D-4485-A62F-7EBADCCAAF33Q41295156-296F811F-FD23-4090-A2FF-EE7FF7E15CF6Q44291604-36539558-0D29-4C22-AA43-3CE65045685BQ45261834-E63A3B14-136D-4E5B-B0EC-54981B91E0D6Q48203946-C7B32C72-6CBE-44E4-AE72-CEFB362B6344Q50775736-93555F10-0B4B-4432-AC6B-764AF6A2BA77
P2860
Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Antibody formation during intr ...... apy with Erwinia asparaginase.
@en
Antibody formation during intr ...... apy with Erwinia asparaginase.
@nl
type
label
Antibody formation during intr ...... apy with Erwinia asparaginase.
@en
Antibody formation during intr ...... apy with Erwinia asparaginase.
@nl
prefLabel
Antibody formation during intr ...... apy with Erwinia asparaginase.
@en
Antibody formation during intr ...... apy with Erwinia asparaginase.
@nl
P2093
P356
P1476
Antibody formation during intr ...... apy with Erwinia asparaginase.
@en
P2093
Birgitte Klug Albertsen
Hans-Joachim Müller
Henrik Schrøder
Niels T Carlsen
Preben Jakobsen
Vassilios I Avramis
P2860
P304
P356
10.1002/MPO.10096
P577
2002-05-01T00:00:00Z